Five tumor markers were analyzed clinically in 101 patients with borde
rline ovarian tumors who were treated by the Tokai Ovarian Tumor Study
Group, an association comprising Nagoya University and its affiliated
hospital, between January 1986 and December 1994. The positive rate o
f CA125 was 68.2% in serous tumor and 51.9% in mucinous tumor. The pos
itive rate of CA19-9 was 51.5% in serous tumor and 44.7% in mucinous t
umor. The positive rates and mean serum levels of CA125 in serous and
mucinous tumor by stage had rising tendencies with an increase in each
stage. The mean serum levels of CA19-9 in serous and mucinous tumor b
y stage had rising tendencies with an increase in each stage. CA125 an
d CA19-9 were useful for screening of borderline ovarian tumors. The p
ositive rates of CEA and TPA in mucinous tumor were 32.5 and 27.3%, re
spectively, although none of the patients with serous tumor were posit
ive in CEA and TPA. The positive rates and mean serum levels of CEA in
mucinous tumor by stage had rising tendencies with an increase in eac
h stage. The positive rate of CA72-4 was significantly lower than that
of CA125 (P < 0.05). (C) 1996 Academic Press, Inc.